Dratch Laynie, Bardakjian Tanya M, Johnson Kelsey, Babaian Nareen, Gonzalez-Alegre Pedro, Elman Lauren, Quinn Colin, Guo Michael H, Scherer Steven S, Amado Defne A
Department of Neurology, University of Pennsylvania, Philadelphia, PA 19104, USA.
Sarepta Therapeutics Inc., Cambridge, MA 02142, USA.
Biology (Basel). 2024 Feb 2;13(2):93. doi: 10.3390/biology13020093.
Advances in gene-specific therapeutics for patients with neuromuscular disorders (NMDs) have brought increased attention to the importance of genetic diagnosis. Genetic testing practices vary among adult neuromuscular clinics, with multi-gene panel testing currently being the most common approach; follow-up testing using broad-based methods, such as exome or genome sequencing, is less consistently offered. Here, we use five case examples to illustrate the unique ability of broad-based testing to improve diagnostic yield, resulting in identification of neuropathy, -related disease, -ALS, related progressive gait decline and spasticity, and -related cerebellar ataxia, deafness, narcolepsy, and hereditary sensory neuropathy type 1E. We describe in each case the technological advantages that enabled identification of the causal gene, and the resultant clinical and personal implications for the patient, demonstrating the importance of offering exome or genome sequencing to adults with NMDs.
神经肌肉疾病(NMDs)患者基因特异性治疗方法的进展使人们更加关注基因诊断的重要性。成人神经肌肉诊所的基因检测方法各不相同,目前多基因panel检测是最常用的方法;而采用外显子组或基因组测序等广泛方法进行的后续检测提供得不太一致。在此,我们用五个病例来说明广泛检测在提高诊断率方面的独特能力,从而识别出与神经病变、相关疾病、肌萎缩侧索硬化症(ALS)、相关进行性步态衰退和痉挛,以及相关小脑共济失调、耳聋、发作性睡病和1E型遗传性感觉神经病。我们在每个病例中描述了能够识别致病基因的技术优势,以及对患者产生的临床和个人影响,证明了为患有NMDs的成年人提供外显子组或基因组测序的重要性。